Atrial fibrillation clinical trials pave the way for the future of treating and managing the heart disorder. The findings from clinical trials offer insights into new therapies, technologies, and strategies for improving patient care. Because atrial fibrillation management is complex, any advantage clinicians can provide to patients is critical. 

Clinician awareness of ongoing, recruiting atrial fibrillation clinical trials is greatly beneficial to patients. That awareness can usher patients to therapies and treatment options that may benefit them more than existing treatments have. Clinical trials not only empower clinicians and patients with more choices for treatment, but it can contribute to clinician-patient collaboration that makes the management of atrial fibrillation smoother.

The following US-based clinical trials represent some of the many ongoing clinical trials for atrial fibrillation taking place around the world.

Atrial Fibrillation Clinical Trials Currently Recruiting  
Study TitlePhaseEstimated EnrollmentStudy StartEstimated Completion
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation3200April 2025June 2028
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR3153October 2024December 2026
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation35350July 2023July 2029
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)31900December 2022October 2026
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation3220April 2023December 2026
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG33200December 2019August 2026
Ongoing Phase 3 Clinical Trials for Atrial Fibrillation

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

  • Sponsor: University of Chicago
  • Goal: The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
    Interventions: Semaglutide, Placebo
  • Primary Outcome Measures: Time to first AF event detected by routine outpatient monitoring; Change from baseline in AF burden detected by routine outpatient monitoring.
  • Timeframe: Baseline to week 68; Baseline to week 68.
  • Study Details
  • Source

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR (ATRIUM)

  • Sponsor: Wake Forest University Health Sciences
  • Goal: The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
  • Interventions: Magnesium Sulfate 2 G, Magnesium Sulfate 4 G, Saline
  • Primary Outcome Measures: Ventricular rate control.
  • Timeframe: Within the first 2 hours of intravenous magnesium administration.
  • Study Details
  • Source

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

  • Sponsor: Johns  Hopkins University
  • Goal: REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
  • Interventions: AFSW Guided DOAC, Continuous DOAC therapy
  • Primary Outcome Measures: To assess whether AFSW-guided, time-delimited DOAC therapy is non-inferior to continuous DOAC therapy for a composite endpoint that includes: (1) Ischemic stroke; (2) Systemic embolism; (3) All-cause mortality.
  • Timeframe: At 60 months.
  • Study Details
  • Source

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

  • Sponsor: Anthos Therapeutics, Inc.
  • Goal: A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
  • Interventions: Abelacimab, Placebo
  • Primary Outcome Measures: Efficacy: Time to first event of ischemic stroke or systemic embolism (SE); Safety: Time to first occurrence of Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding.
  • Timeframe: Up to 30 months; Up to 30 months.
  • Study Details
  • Source

A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation

  • Sponsor: Mayo Clinic
  • Goal: The purpose of this study is to test if a nerve block procedure called a stellate ganglion block can help decrease the chance of atrial fibrillation after surgery.
  • Interventions: Stellate ganglion block, Bupivacaine, Placebo
  • Primary Outcome Measures: Incidence of atrial fibrillation.
  • Timeframe: Within one week of surgery or during hospitalization if discharged prior to one week.
  • Study Details
  • Source

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

  • Sponsor: Icahn School of Medicine at Mount Sinai
  • Goal: The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.
  • Interventions: Antiplatelet-only strategy, Oral anticoagulant plus background antiplatelet therapy.
  • Primary Outcome Measures: Composite of death, ischemic stroke, TIA, MI, systemic arterial thromboembolism or venous thromboembolism (DVT and/or PE); Any BARC type 3 or 5.
  • Timeframe: Up to 180 days after randomization; 90 days after randomization.
  • Study Details
  • Source
Related Guidelines:

Surgical Treatment of Atrial Fibrillation

  • Society of Thoracic Surgeons
  • January 2024

Management of Atrial Fibrillation

  • American College of Cardiology/American Heart Association/Heart Rhythm Society/American College of Clinical Pharmacy
  • November 2023

Catheter and Surgical Ablation of Atrial Fibrillation

  • European Heart Rhythm Society/Hearth Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society
  • September 2024

Sign up for alerts and stay informed on the latest published clinical guideline updates and the clinical trials that may influence them.

Copyright © 2025 Guideline Central, all rights reserved.